יחס מהיר: Cogent Biosciences (COGT)

Cogent Biosciences (COGT) is developing a highly scalable targeted therapy model, where drug patents enable the generation of superprofits with low production costs. The startup attracts leading oncologists through a flexible approach to research and generous stock options. Business success depends on the outcome of clinical trials in the race for niche markets. The quick ratio is 14.01, as reflected by the shares on this price chart.

For Cogent Biosciences (COGT), burdened by R&D expenses amid a revenue deficit, this indicator is critically important as it compares the most liquid assets against short-term liabilities while ignoring illiquid inventories. By analyzing the quick ratio, an investor assesses the company's actual ability to settle debts without external funding, which under current conditions reveals a dangerous dependence on the depletion of cash reserves.